西黄胶囊联合恩度及PC方案治疗驱动基因阴性且PD-L1表达阴性老年晚期非鳞非小细胞肺癌的疗效  

Effects of Xihuang Capsules combined with Endu and PC regimen in the treatment of senile advanced non-squamous non-small cell lung cancer with negative driver gene and negative PD-L1 expression

作　　者：裴克[1] 刘彩虹[1] 李军芳[1] PEI Ke;LIU Caihong;LI Junfang(Department of Pharmacy,the First Affiliated Hospital of He’nan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学第一附属医院药学部,洛阳471003

出　　处：《西北药学杂志》2025年第2期126-133,共8页Northwest Pharmaceutical Journal

基　　金：河南省医学科技攻关计划项目(编号:LHGJ20210630)。

摘　　要：目的探讨西黄胶囊联合恩度及PC方案(即培美曲塞+卡铂)治疗驱动基因阴性且程序性细胞死亡蛋白1配体1(programmed cell death ligand 1,PD-L1)表达阴性的老年晚期非鳞非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效和安全性。方法选取2020年6月—2023年5月收治的驱动基因阴性且PD-L1表达阴性的94例老年晚期非鳞NSCLC患者作为研究对象,用随机数字表法分为观察组和对照组,每组47例。对照组采取恩度联合PC方案治疗,在此基础上观察组联合西黄胶囊治疗,连续治疗4个疗程后评价2组的近期疗效。比较治疗前后2组的血清肿瘤标志物水平、癌症治疗功能评价系统-肺癌模块(functional assessment of cancer treatment-lung,FACT-L)评分。统计2组不良反应的发生情况,并对所有对象进行长期追踪随访,记录其无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)。结果观察组的疾病控制率为91.49%(43/47),较对照组[76.60%(36/47)]显著提高(P<0.05)。治疗后,2组的血清癌胚抗原(carcinoembryonic antigen,CEA)、细胞角蛋白片段19(cytokeratin-19-fragment antigen 21-1,CYFR21-1)、糖类抗原125(carbohydrate antigen 125,CA125)水平均显著降低(P<0.05),且观察组均低于对照组(P<0.05)。治疗后,2组的FACT-L中社会/家庭状况领域评分与治疗前相比及组间同期比较差异均无统计学意义(P>0.05)。治疗后,2组FACT-L中生理状况、功能状况、附加关注情况等其余各领域评分及量表总分均显著上升(P<0.05),且观察组上升得更显著(P<0.05)。观察组中性粒细胞减少、胃肠道反应的发生率分别为25.53%(12/47)、57.45%(27/47),较对照组[46.81%(22/47)、76.60%(36/47)]均显著降低(P<0.05)。2组贫血、心脏毒性、肾损害、肝损害等其余各项不良反应发生率比较差异均无统计学意义(P>0.05)。观察组的中位PFS、中位OS分别为6.7个月(95%CI:4.48~8.35)、14.8个月(95%CI:10.03~18.44),较对照�Objective To explore the clinical efficacy and safety of Xihuang Capsules combined with Endu and PC regimen(pemetrexed+carboplatin)in the treatment of programmed cell death protein-1 ligand 1(PD-L1)negative driver gene and negative PD-L1 expression elder patients with elderly with advanced non-squamous non-small cell lung cancer(NSCLC).Methods A total of 94 elderly patients with advanced non-squamous NSCLC with negative driver gene and negative PD-L1 expression treated from June 2020 to May 2023 were enrolled and divided into observation group and control group by random number table method,with 47 cases in each group.The control group was treated with Endu combined with PC,on this basis,the observation group was treated with Xihuang Capsules,and the short-term efficacy of the 2 groups was evaluated after 4 consecutive courses of treatment.The serum tumor markers and functional assessment of cancer treatment-lung(FACT-L)scores of the 2 groups were compared before and after treatment.The occurrence of adverse reactions in the 2 groups was analyzed,and all subjects were followed up for a long time,and progression-free survival(PFS)and overall survival(OS)were recorded.Results The disease control rate of the observation group was 91.49%(43/47),which was significantly higher than that of the control group[76.60%(36/47)](P<0.05)After treatment,the serum carcinoembryonic antigen(CEA),cytokeratin-19-fragment antigen 21-1,cytokeratin-19-fragment antigen 21-1,CYFR21-1)and carbohydrate antigen 125(CA125)levels were significantly decreased(P<0.05),and the observation group was lower than control group(P<0.05).After treatment,there was no significant difference in social/family status field scores in FACT-L between the 2 groups compared with before treatment and between the groups at the same period(P>0.05).After treatment,the scores in other areas of FACT-L,such as physiological status,functional status and additional attention,and the total score of the scale were significantly increased in both groups(P<0.05),especially i

关 键 词：非小细胞肺癌 西黄胶囊 抗血管生成 化疗 

分 类 号：R979.1[医药卫生—药品]